Pharma sector is currently going through a volatile phase with companies shifting business models, either by divesting or swapping their non-profitable business units. The latest story is of Sanofi (SNY), which is selling off certain assets in a move to streamline the company.
The Paris-headquartered company plans to offload its European generics business Zentiva that it acquired in 2009. Several bidders had earlier dropped out of an auction, but latest news suggests that the company is nearing an agreement and may soon finalize the sale.
According to Reuters, private equity firm Advent International has shown interest in acquiring the generic drug arm from the French healthcare company for about $2.48 billion (1.9 billion euros) including equity and debt.
Sanofi decided to divest Zentiva, which focuses on generic pharma products, as a part of its 2020 strategic initiative. The sale is expected to be completed by the end of this year.
Several Indian pharma giants had also shown interest in acquiring Sanofi’s portfolio that includes cardiovascular and gastrointestinal medications, primarily because of its high growth potential in the East European markets.
Private equity firm Advent International has shown interest in acquiring the generic drug arm from the French healthcare company for about $2.48 billion (1.9 billion euros) including equity and debt.
Sanofi, which recently snapped Belgian drug company Ablynx in a deal worth $4.8 billion, had earlier planned to divest the generic business unit in 2015. But Olivier Brandicourt, who had stepped in as the new CEO, engaged in other deal-making activities. In an asset swap in 2016, the company handed over its animal health unit Merial to Boehringer Ingelheim and got consumer health business of the latter in return.
The company is basically shifting its focus to the specialty care and is boosting its R&D pipeline.
In a similar move only a day back, UK-based Shire (SHPG) sold its oncology business to France’s Servier Laboratories for about $2.4 billion.
Most Popular
AMAT Earnings: Applied Materials Q1 2025 adj. profit rises on higher sales
Applied Materials, Inc. (NASDAQ: AMAT), a leading supplier of equipment and software for manufacturing semiconductor chips and flat panel displays, Thursday reported an increase in sales and adjusted earnings for
Cisco Systems (CSCO) bets on strong AI demand to drive growth
After starting the fiscal year on a weak note, Cisco Systems Inc. (NASDAQ: CSCO) has regained momentum, reporting higher second-quarter revenue and profit that beat analysts’ estimates. The company is
What to expect when Hasbro (HAS) reports its fourth quarter 2024 earnings results
Shares of Hasbro, Inc. (NASDAQ: HAS) stayed green on Thursday. The stock has gained 7% year-to-date. The toymaker is scheduled to report its fourth quarter 2024 earnings results on Thursday,